Your search for non small cell lung cancer returned 29 results

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer.

The designation is supported by data from the ongoing phase 2 KEYNOTE-942 study, which included 157 patients with stage III/IV melanoma following complete resection.

Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse

Is lung cancer screening using risk-based low-dose computer tomography a better predictor of lung cancer risk than age or pack/years of smoking?

Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.

Drug was to be used alongside chemotherapy for patients with metastatic non-small cell lung cancer

The decision was made to withdraw the application after the Companies and the FDA were not able to align on certain postmarketing studies.

Life-space assessments may help older adults better understand how cancer treatment impacts their lives, authors say

Higher major pathological response seen for patients with resectable NSCLC treated with combo versus durvalumab alone.